KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Novavax (NVAX) EBIAT (2016 - 2025)

Novavax has reported EBIAT over the past 16 years, most recently at $17.5 million for Q4 2025.

  • Quarterly results put EBIAT at $17.5 million for Q4 2025, up 121.63% from a year ago — trailing twelve months through Dec 2025 was $440.3 million (up 334.8% YoY), and the annual figure for FY2025 was $440.3 million, up 334.83%.
  • EBIAT for Q4 2025 was $17.5 million at Novavax, up from -$202.4 million in the prior quarter.
  • Over the last five years, EBIAT for NVAX hit a ceiling of $518.6 million in Q1 2025 and a floor of -$846.3 million in Q4 2021.
  • Median EBIAT over the past 5 years was -$158.1 million (2022), compared with a mean of -$134.7 million.
  • Biggest five-year swings in EBIAT: tumbled 1910.83% in 2021 and later surged 451.47% in 2025.
  • Novavax's EBIAT stood at -$846.3 million in 2021, then soared by 78.46% to -$182.2 million in 2022, then grew by 2.12% to -$178.4 million in 2023, then surged by 54.58% to -$81.0 million in 2024, then surged by 121.63% to $17.5 million in 2025.
  • The last three reported values for EBIAT were $17.5 million (Q4 2025), -$202.4 million (Q3 2025), and $106.5 million (Q2 2025) per Business Quant data.